#1 Clinical Trials Search in Europe

A24110He

A new clinical trial is underway to assess the safety and effectiveness of A24110He, a promising drug for patients with type 2 diabetes and elevated triglyceride levels. This phase 2 study aims to evaluate the drug’s safety, local tolerability, and pharmacodynamic profile through multiple doses in a controlled setting. The trial’s findings could potentially lead to improved treatment options for individuals struggling with these conditions.

Table of Contents

What is A24110He?

A24110He is a new investigational drug being studied for its potential to help people with type 2 diabetes who also have high levels of triglycerides in their blood[1]. It belongs to a class of drugs called antisense oligonucleotides (ASOs), which are designed to target specific genetic instructions in the body[1].

Medical Conditions Treated

The main condition that A24110He aims to treat is called moderate to severe hypertriglyceridemia[1]. This is a medical term that means having high levels of triglycerides (a type of fat) in the blood. Specifically, the drug is being tested in people who have:

  • Type 2 diabetes: A condition where the body doesn’t use insulin properly, leading to high blood sugar levels
  • Elevated triglycerides: Fasting triglyceride levels of 2.5 mmol/L or higher

How A24110He Works

While the exact mechanism isn’t fully described in the trial information, A24110He is an antisense oligonucleotide (ASO)[1]. ASOs work by interfering with the genetic instructions that lead to the production of certain proteins in the body. In this case, A24110He likely targets genes involved in triglyceride production or metabolism, aiming to lower triglyceride levels in the blood.

Clinical Trial Details

A24110He is currently being studied in a Phase 2 clinical trial[1]. Here are some key details about the study:

  • It’s a randomized, double-blind, placebo-controlled trial. This means that participants are randomly assigned to receive either A24110He or a placebo, and neither the participants nor the researchers know who is receiving which treatment during the study[1].
  • The drug is given as a subcutaneous injection (an injection under the skin)[1].
  • Participants receive four weekly administrations of the drug[1].
  • The main goal is to evaluate the safety and local tolerability of A24110He[1].
  • Secondary goals include studying how the drug is processed by the body (pharmacokinetics) and how it affects triglyceride levels (pharmacodynamics)[1].

Eligibility Criteria

The study has specific criteria for who can participate. Some key eligibility factors include:

  • Age 18-75 years[1]
  • Body Mass Index (BMI) less than 38 kg/m² and body weight of at least 56 kg[1]
  • History of hypertriglyceridemia (high triglycerides)[1]
  • Fasting triglyceride levels of 2.5 mmol/L or higher[1]
  • For those with type 2 diabetes, stable glucose-lowering treatment for at least 3 months[1]

There are also several exclusion criteria, such as recent major health events, certain medications, and other health conditions that might interfere with the study results[1].

Safety and Monitoring

The trial includes extensive safety monitoring to protect participants’ health. This includes:

  • Physical examinations[1]
  • Vital signs monitoring: Including blood pressure, heart rate, and body temperature[1]
  • Blood tests: To check liver function, kidney function, blood sugar levels, and other important health indicators[1]
  • Urine tests[1]
  • Monitoring for side effects: The frequency, seriousness, and intensity of any adverse events will be closely tracked[1]

Potential Benefits

While it’s important to note that A24110He is still in the testing phase and its benefits are not yet proven, the potential advantages being studied include:

  • Lowering of triglyceride levels in the blood[1]
  • Possible improvement in overall metabolic health for people with type 2 diabetes and high triglycerides[1]

It’s crucial to remember that more research is needed to fully understand the effects and potential benefits of A24110He. The ongoing clinical trial will provide important information about its safety and effectiveness.

Aspect Details
Study Type Phase 2, randomized, double-blind, placebo-controlled trial
Drug A24110He (antisense oligonucleotide)
Target Condition Type 2 diabetes with elevated triglycerides
Administration Four weekly subcutaneous injections
Primary Objectives Safety and local tolerability evaluation
Secondary Objectives Exposure and pharmacodynamic profile assessment
Key Inclusion Criteria Age 18-75, history of hypertriglyceridemia, fasting triglycerides ≥ 2.5 mmol/L, stable type 2 diabetes treatment
Key Exclusion Criteria Recent cardiovascular events, uncontrolled hypertension, HbA1c >70 mmol/mol, active malignancy
Primary Endpoints Physical examination, local tolerability, vital signs, safety lab tests, adverse events
Secondary Endpoints Plasma concentrations of A24110He, pharmacokinetic parameters, fasting triglyceride levels

FAQ

  • What is A24110He? A24110He is an antisense oligonucleotide (ASO) being studied as a potential treatment for patients with type 2 diabetes and high triglyceride levels. It is administered through subcutaneous injection.
  • What is the main goal of this clinical trial? The main objective of this trial is to evaluate the safety and local tolerability of A24110He when administered in multiple doses to subjects with elevated plasma triglyceride concentrations.
  • Who can participate in this trial? Participants must be between 18-75 years old, have a history of hypertriglyceridemia, fasting triglyceride levels ≥ 2.5 mmol/L, and type 2 diabetes with stable glucose-lowering treatment. They must also meet other specific inclusion criteria and not fall under any exclusion criteria.
  • How is the drug administered in this trial? A24110He is administered through subcutaneous injection. The trial involves four weekly administrations of either A24110He or a placebo.
  • What are the potential benefits of participating in this trial? While individual benefits cannot be guaranteed, participants contribute to the advancement of medical knowledge and potential development of new treatments for type 2 diabetes and high triglycerides. They also receive close medical monitoring throughout the trial.

Ongoing Clinical Trials on A24110He

  • Study on the Safety of A24110He for Patients with Type 2 Diabetes and High Triglycerides

    Not recruiting

    2 1 1
    Investigated drugs:
    Sweden

Glossary

  • Hypertriglyceridemia: A condition characterized by elevated levels of triglycerides (a type of fat) in the blood, which can increase the risk of heart disease and other health problems.
  • Type 2 Diabetes: A chronic condition that affects the way your body processes blood sugar (glucose), characterized by high blood sugar levels due to insulin resistance or insufficient insulin production.
  • Antisense Oligonucleotide (ASO): A type of synthetic DNA-like molecule designed to bind to specific RNA sequences and potentially modify gene expression or protein production.
  • Pharmacodynamic Profile: The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Subcutaneous Injection: A method of administering medication by injecting it into the layer of tissue between the skin and muscle.
  • Double-blind: A study design where neither the participants nor the researchers directly involved know who is receiving the actual treatment and who is receiving a placebo.
  • Placebo: An inactive substance that looks like the drug being tested but has no therapeutic effect, used as a control in clinical trials.
  • HbA1c: A blood test that measures average blood sugar levels over the past 2-3 months, commonly used to diagnose and monitor diabetes.
  • Fasting Plasma Glucose (FPG): A blood test that measures glucose levels after an 8-hour fast, used to diagnose and monitor diabetes.
  • Body Mass Index (BMI): A measure that uses your height and weight to work out if your weight is healthy, calculated by dividing weight in kilograms by height in meters squared.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-of-a24110he-for-patients-with-type-2-diabetes-and-high-triglycerides/